Tesaro Inc (TSRO) 88.70 $TSRO
ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial
GlobeNewswire - Fri Jul 08, 3:05PM CDT
-- The ENGOT-OV16/NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort
TSRO: 88.70 (-3.26)
TESARO Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters
GlobeNewswire - Thu Jul 07, 3:05PM CDT
TESARO, Inc. (Nasdaq:TSRO) today announced the closing of its previously announced underwritten public offering of common stock. TESARO sold 5,347,500 shares of its common stock at an offering price to the public of $81.00 per share, which included 697,500 shares of common stock sold pursuant to the full exercise of the underwriters' option. TESARO estimates that the net proceeds from the offering will be approximately $409.0 million, after deducting the underwriting discount and other offering expenses payable by TESARO. Citigroup, Leerink Partners, Credit Suisse and Wells Fargo Securities acted as bookrunners, and Guggenheim Securities, Mizuho Securities, Raymond James, SunTrust Robinson Humphrey and Wedbush PacGrow acted as co-managers for the offering.
TSRO: 88.70 (-3.26)
Myriad Genetics myChoice Cancer Test Findings Encourage
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 8:34AM CDT
With respect to myChoice HRD test, Myriad earlier noted that it expects to serve a worldwide market size of $18.5 billion (compared with the current market size of $5.6 billion).
MYGN: 31.69 (+0.81), TSRO: 88.70 (-3.26), HSKA: 43.52 (+2.33), INVA: 11.64 (+0.26)
Tesaro (TSRO) in Focus: Stock Adds 8.6% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 7:29AM CDT
Tesaro, Inc. (TSRO) shares rose almost 9% in the last trading session.
TSRO: 88.70 (-3.26), ORPN: 1.67 (+0.08)
Tesaro Stock Up on Successful Phase III Ovarian Cancer Trial
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 5:31PM CDT
Shares of Tesaro, Inc. (TSRO) surged 108% after the company announced that its phase III trial, NOVA, on oncology drug niraparib successfully achieved the primary endpoint of progression-free survival (PFS).
JNJ: 122.85 (+0.34), TSRO: 88.70 (-3.26), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
Clovis Oncology (CLVS) Jumps: Stock Adds 21.9% in Session
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 7:15AM CDT
Clovis Oncology, Inc. (CLVS) shares rose almost 22% in the last trading session.
TSRO: 88.70 (-3.26), CLVS: 14.73 (+0.03)
TESARO Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Jun 30, 5:38AM CDT
TESARO, Inc. (NASDAQ:TSRO) announced today that it has commenced an underwritten public offering of $300 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional $45 million of its common stock. Citigroup, Leerink Partners, Credit Suisse and Wells Fargo Securities are acting as bookrunners, and Mizuho, Raymond James, SunTrust Robinson Humphrey and Wedbush PacGrow are acting as co-managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
TSRO: 88.70 (-3.26)
Nike, GE and PrivateBancorp climb, Esperion tumbles
AP - Wed Jun 29, 3:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Wednesday:
AYI: 264.62 (+10.99), NFX: 43.82 (+1.05), GE: 32.20 (+0.38), TSRO: 88.70 (-3.26), NKE: 56.72 (+0.80)
Why Investors Love These Biotech's Stocks? - Cellectar Biosciences, Xenoport, Rexahn Pharma, and Tesaro
PR Newswire - Wed Jun 29, 6:45AM CDT
The Biotech industry has seen pressure with pricing, policies, and economic uncertainties, but still it continues to present a number of great trades. Stock-Callers.com reviews the performances of the following companies at yesterday's close and see if they are worthy of consideration: Cellectar Biosciences Inc. (NASDAQ: CLRB), Xenoport Inc. (NASDAQ: XNPT), Rexahn Pharmaceuticals Inc. (NYSE: RNN), and Tesaro Inc. (NASDAQ: TSRO). Learn more about these stocks and receive your complimentary trade alerts at:
CLRB: 3.31 (-0.10), RNN: 0.25 (-0.01), TSRO: 88.70 (-3.26), XNPT: 7.07 (+0.05)
TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer
GlobeNewswire - Thu Jun 23, 5:30PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced nine presentations of rolapitant data at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 23 to 25, 2016, in Adelaide, Australia.
TSRO: 88.70 (-3.26)
Noteworthy Thursday Option Activity: TSRO, MRVL, AKS
DividendChannel.com - Thu Jun 16, 2:35PM CDT
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Tesaro Inc , where a total volume of 2,802 contracts has been traded thus far today, a contract volume which is representative of...
TSRO: 88.70 (-3.26)
TESARO Provides Pipeline Update at ASCO Investor Briefing
GlobeNewswire - Sat Jun 04, 6:00PM CDT
-- Rolapitant IV NDA accepted for review by FDA; PDUFA date is January 11, 2017
TSRO: 88.70 (-3.26)
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 48.75 (-0.08), SQNM: 0.92 (+0.03), TSRO: 88.70 (-3.26), NKTR: 14.92 (+0.62)
TESARO Congratulates Dr. Mary Lynne Hedley on Being Named Life Science "Entrepreneur of the Year" by the New England Venture Capital Association
GlobeNewswire - Thu May 19, 4:46PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to congratulate co-founder, President and COO Dr. Mary Lynne Hedley on being named the Life Science "Entrepreneur of the Year" by the New England Venture Capital Association. The 2016 NEVY Awards celebrate New England's Life Science and Tech communities.
TSRO: 88.70 (-3.26)
TESARO Announces Five Abstracts to be Presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Wed May 18, 4:30PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of five abstracts at the 2016 American Society of Clinical Oncology (ASCO) annual meeting, June 3 to June 7, 2016, in Chicago. In addition, TESARO will host an investor and analyst briefing in Chicago on Saturday, June 4 at 6:15 PM local time in conjunction with the ASCO annual meeting.
TSRO: 88.70 (-3.26)
WuXi Biologics Congratulates TESARO for Anti-TIM-3 Antibody IND Submission in the U.S.
PR Newswire - Tue May 10, 7:00AM CDT
WuXi Biologics (WuXi), a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, announced today that its partner TESARO submitted an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration.
TSRO: 88.70 (-3.26)
Tesaro reports 1Q loss
Automated Insights - Thu May 05, 6:21PM CDT
WALTHAM, Mass. (AP) _ Tesaro Inc. (TSRO) on Thursday reported a loss of $90.8 million in its first quarter.
TSRO: 88.70 (-3.26)
TESARO Announces First-Quarter 2016 Operating Results
GlobeNewswire - Thu May 05, 3:06PM CDT
-- U.S. launch of VARUBI(R) underway; New Drug Application (NDA) for IV formulation of rolapitant submitted
TSRO: 88.70 (-3.26)
TESARO Announces Submission of Investigational New Drug Application for Anti-TIM-3 Antibody TSR-022 to the U.S. FDA
GlobeNewswire - Mon Apr 25, 7:05AM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration. TSR-022 is a monoclonal antibody drug candidate targeting TIM-3.
TSRO: 88.70 (-3.26)
TESARO to Announce First Quarter 2016 Financial Results on May 5, 2016
GlobeNewswire - Thu Apr 21, 3:05PM CDT
TESARO, Inc. (NASDAQ:TSRO) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on May 5, 2016 to discuss the Company's operating results in greater detail, as well as the status of its development programs and the VARUBI(R) launch.
TSRO: 88.70 (-3.26)
ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial
GlobeNewswire - Fri Jul 08, 3:05PM CDT
-- The ENGOT-OV16/NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort
TSRO: 88.70 (-3.26)
TESARO Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters
GlobeNewswire - Thu Jul 07, 3:05PM CDT
TESARO, Inc. (Nasdaq:TSRO) today announced the closing of its previously announced underwritten public offering of common stock. TESARO sold 5,347,500 shares of its common stock at an offering price to the public of $81.00 per share, which included 697,500 shares of common stock sold pursuant to the full exercise of the underwriters' option. TESARO estimates that the net proceeds from the offering will be approximately $409.0 million, after deducting the underwriting discount and other offering expenses payable by TESARO. Citigroup, Leerink Partners, Credit Suisse and Wells Fargo Securities acted as bookrunners, and Guggenheim Securities, Mizuho Securities, Raymond James, SunTrust Robinson Humphrey and Wedbush PacGrow acted as co-managers for the offering.
TSRO: 88.70 (-3.26)
Myriad Genetics myChoice Cancer Test Findings Encourage
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 8:34AM CDT
With respect to myChoice HRD test, Myriad earlier noted that it expects to serve a worldwide market size of $18.5 billion (compared with the current market size of $5.6 billion).
MYGN: 31.69 (+0.81), TSRO: 88.70 (-3.26), HSKA: 43.52 (+2.33), INVA: 11.64 (+0.26)
Tesaro (TSRO) in Focus: Stock Adds 8.6% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 7:29AM CDT
Tesaro, Inc. (TSRO) shares rose almost 9% in the last trading session.
TSRO: 88.70 (-3.26), ORPN: 1.67 (+0.08)
Tesaro Stock Up on Successful Phase III Ovarian Cancer Trial
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 5:31PM CDT
Shares of Tesaro, Inc. (TSRO) surged 108% after the company announced that its phase III trial, NOVA, on oncology drug niraparib successfully achieved the primary endpoint of progression-free survival (PFS).
JNJ: 122.85 (+0.34), TSRO: 88.70 (-3.26), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
Clovis Oncology (CLVS) Jumps: Stock Adds 21.9% in Session
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 7:15AM CDT
Clovis Oncology, Inc. (CLVS) shares rose almost 22% in the last trading session.
TSRO: 88.70 (-3.26), CLVS: 14.73 (+0.03)
TESARO Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Jun 30, 5:38AM CDT
TESARO, Inc. (NASDAQ:TSRO) announced today that it has commenced an underwritten public offering of $300 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional $45 million of its common stock. Citigroup, Leerink Partners, Credit Suisse and Wells Fargo Securities are acting as bookrunners, and Mizuho, Raymond James, SunTrust Robinson Humphrey and Wedbush PacGrow are acting as co-managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
TSRO: 88.70 (-3.26)
Nike, GE and PrivateBancorp climb, Esperion tumbles
AP - Wed Jun 29, 3:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Wednesday:
AYI: 264.62 (+10.99), NFX: 43.82 (+1.05), GE: 32.20 (+0.38), TSRO: 88.70 (-3.26), NKE: 56.72 (+0.80)
Why Investors Love These Biotech's Stocks? - Cellectar Biosciences, Xenoport, Rexahn Pharma, and Tesaro
PR Newswire - Wed Jun 29, 6:45AM CDT
The Biotech industry has seen pressure with pricing, policies, and economic uncertainties, but still it continues to present a number of great trades. Stock-Callers.com reviews the performances of the following companies at yesterday's close and see if they are worthy of consideration: Cellectar Biosciences Inc. (NASDAQ: CLRB), Xenoport Inc. (NASDAQ: XNPT), Rexahn Pharmaceuticals Inc. (NYSE: RNN), and Tesaro Inc. (NASDAQ: TSRO). Learn more about these stocks and receive your complimentary trade alerts at:
CLRB: 3.31 (-0.10), RNN: 0.25 (-0.01), TSRO: 88.70 (-3.26), XNPT: 7.07 (+0.05)
TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer
GlobeNewswire - Thu Jun 23, 5:30PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced nine presentations of rolapitant data at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 23 to 25, 2016, in Adelaide, Australia.
TSRO: 88.70 (-3.26)
Noteworthy Thursday Option Activity: TSRO, MRVL, AKS
DividendChannel.com - Thu Jun 16, 2:35PM CDT
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Tesaro Inc , where a total volume of 2,802 contracts has been traded thus far today, a contract volume which is representative of...
TSRO: 88.70 (-3.26)
TESARO Provides Pipeline Update at ASCO Investor Briefing
GlobeNewswire - Sat Jun 04, 6:00PM CDT
-- Rolapitant IV NDA accepted for review by FDA; PDUFA date is January 11, 2017
TSRO: 88.70 (-3.26)
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 48.75 (-0.08), SQNM: 0.92 (+0.03), TSRO: 88.70 (-3.26), NKTR: 14.92 (+0.62)
TESARO Congratulates Dr. Mary Lynne Hedley on Being Named Life Science "Entrepreneur of the Year" by the New England Venture Capital Association
GlobeNewswire - Thu May 19, 4:46PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to congratulate co-founder, President and COO Dr. Mary Lynne Hedley on being named the Life Science "Entrepreneur of the Year" by the New England Venture Capital Association. The 2016 NEVY Awards celebrate New England's Life Science and Tech communities.
TSRO: 88.70 (-3.26)
TESARO Announces Five Abstracts to be Presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Wed May 18, 4:30PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of five abstracts at the 2016 American Society of Clinical Oncology (ASCO) annual meeting, June 3 to June 7, 2016, in Chicago. In addition, TESARO will host an investor and analyst briefing in Chicago on Saturday, June 4 at 6:15 PM local time in conjunction with the ASCO annual meeting.
TSRO: 88.70 (-3.26)
WuXi Biologics Congratulates TESARO for Anti-TIM-3 Antibody IND Submission in the U.S.
PR Newswire - Tue May 10, 7:00AM CDT
WuXi Biologics (WuXi), a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, announced today that its partner TESARO submitted an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration.
TSRO: 88.70 (-3.26)
Tesaro reports 1Q loss
Automated Insights - Thu May 05, 6:21PM CDT
WALTHAM, Mass. (AP) _ Tesaro Inc. (TSRO) on Thursday reported a loss of $90.8 million in its first quarter.
TSRO: 88.70 (-3.26)
TESARO Announces First-Quarter 2016 Operating Results
GlobeNewswire - Thu May 05, 3:06PM CDT
-- U.S. launch of VARUBI(R) underway; New Drug Application (NDA) for IV formulation of rolapitant submitted
TSRO: 88.70 (-3.26)
TESARO Announces Submission of Investigational New Drug Application for Anti-TIM-3 Antibody TSR-022 to the U.S. FDA
GlobeNewswire - Mon Apr 25, 7:05AM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration. TSR-022 is a monoclonal antibody drug candidate targeting TIM-3.
TSRO: 88.70 (-3.26)
TESARO to Announce First Quarter 2016 Financial Results on May 5, 2016
GlobeNewswire - Thu Apr 21, 3:05PM CDT
TESARO, Inc. (NASDAQ:TSRO) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on May 5, 2016 to discuss the Company's operating results in greater detail, as well as the status of its development programs and the VARUBI(R) launch.
TSRO: 88.70 (-3.26)
